The Middle East DNA synthesis market size was estimated at USD 44.7 million in 2024 and is projected to reach USD 143.3 million by 2033, growing at a CAGR of 14.29% from 2025 to 2033. Increasing investments in biotechnology, developing research initiatives in genomics, and rising demand for synthetic biology applications across healthcare and industrial sectors in the region drive this growth.
Rising academic and clinical research activity is a significant driver of the DNA synthesis industry in the Middle East. Over the past decade, the region has witnessed substantial growth in research infrastructure, with governments and private stakeholders investing in universities, research centers, and teaching hospitals. Institutions across countries such as Saudi Arabia, the UAE, and Qatar increasingly prioritize genetic and molecular biology research, leading to heightened demand for synthetic DNA tools. These tools are essential for a wide range of applications, including gene editing, cloning, and the development of diagnostic assays. The increased availability of funding for R&D, along with collaborations with international research bodies, is further encouraging the adoption of DNA synthesis technologies in academic settings.
Moreover, the clinical research landscape in the Middle East is expanding, especially in precision medicine and translational genomics. Hospitals and medical research institutions are undertaking more clinical trials and biomarker discovery initiatives to understand disease mechanisms and develop targeted therapies. These efforts often rely heavily on synthetic oligonucleotides and gene constructs, further driving market demand. Moreover, national genomics initiatives such as the Qatar Genome Program and the Saudi Human Genome Program generate large volumes of genetic data, requiring synthetic DNA for validation, analysis, and downstream applications. Integrating genomics into healthcare and clinical decision-making is accelerating the use of DNA synthesis technologies across the region’s medical research ecosystem.
National genomics programs have accelerated this trend by driving large-scale demand for synthetic DNA. Initiatives such as the Saudi Human Genome Program and the Qatar Genome Program are focused on building comprehensive genomic databases to inform population-wide health strategies. These projects require vast amounts of synthetic DNA for sequencing validation, probe development, and functional genomic studies. Moreover, integrating genomic data into electronic health records and clinical workflows encourages hospitals and diagnostic labs to adopt DNA synthesis technologies for routine applications. As precision medicine becomes a central component of regional healthcare agendas, the need for scalable, reliable, and cost-effective DNA synthesis solutions is expected to grow significantly, making it a cornerstone of the market's expansion in the Middle East.
This product will be delivered within 2 business days.
Rising academic and clinical research activity is a significant driver of the DNA synthesis industry in the Middle East. Over the past decade, the region has witnessed substantial growth in research infrastructure, with governments and private stakeholders investing in universities, research centers, and teaching hospitals. Institutions across countries such as Saudi Arabia, the UAE, and Qatar increasingly prioritize genetic and molecular biology research, leading to heightened demand for synthetic DNA tools. These tools are essential for a wide range of applications, including gene editing, cloning, and the development of diagnostic assays. The increased availability of funding for R&D, along with collaborations with international research bodies, is further encouraging the adoption of DNA synthesis technologies in academic settings.
Moreover, the clinical research landscape in the Middle East is expanding, especially in precision medicine and translational genomics. Hospitals and medical research institutions are undertaking more clinical trials and biomarker discovery initiatives to understand disease mechanisms and develop targeted therapies. These efforts often rely heavily on synthetic oligonucleotides and gene constructs, further driving market demand. Moreover, national genomics initiatives such as the Qatar Genome Program and the Saudi Human Genome Program generate large volumes of genetic data, requiring synthetic DNA for validation, analysis, and downstream applications. Integrating genomics into healthcare and clinical decision-making is accelerating the use of DNA synthesis technologies across the region’s medical research ecosystem.
Increasing Focus on Precision Medicine and Genomics
The increasing focus on precision medicine and genomics is emerging as a key driver of the DNA synthesis industry in the Middle East. As countries in the region strive to modernize their healthcare systems, there is a growing emphasis on personalized treatment approaches that cater to the unique genetic profiles of individuals. For instance, in February 2025, a study in Nature Genetics highlighted the Greater Middle East's potential as a global genomics hub for rare diseases, despite data challenges and underutilized genetic diversity. Governments and healthcare institutions are investing in genome sequencing, molecular diagnostics, and genetic screening programs to support early diagnosis and targeted therapies. DNA synthesis plays a crucial role in these initiatives by enabling the design and production of synthetic genes, oligonucleotides, and other molecular tools used in genomic testing, biomarker validation, and developing precision drugs.National genomics programs have accelerated this trend by driving large-scale demand for synthetic DNA. Initiatives such as the Saudi Human Genome Program and the Qatar Genome Program are focused on building comprehensive genomic databases to inform population-wide health strategies. These projects require vast amounts of synthetic DNA for sequencing validation, probe development, and functional genomic studies. Moreover, integrating genomic data into electronic health records and clinical workflows encourages hospitals and diagnostic labs to adopt DNA synthesis technologies for routine applications. As precision medicine becomes a central component of regional healthcare agendas, the need for scalable, reliable, and cost-effective DNA synthesis solutions is expected to grow significantly, making it a cornerstone of the market's expansion in the Middle East.
Middle East DNA Synthesis Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. The analyst has segmented the Middle East DNA synthesis market report based on the service type, application, end use, and country.Service Type Outlook (Revenue, USD Million, 2021-2033)
- Oligonucleotide Synthesis
- By Type
- Standard Oligonucleotide Synthesis
- Custom Oligonucleotide Synthesis
- By Length
- Less than 50 nt
- 51-100 nt
- 101-150 nt
- More than 150 nt
- Gene Synthesis
- By Type
- Custom Gene Synthesis
- Gene Library Synthesis
- By Length
- Less than 500 nt
- 501-1000 nt
- 1001-1500 nt
- 1501-2000 nt
- 2001-2500 nt
- More than 2500 nt
Application Outlook (Revenue, USD Million, 2021-2033)
- Research and Development
- Oligonucleotide Synthesis
- PCR
- NGS
- CRISPR
- Cloning and Mutagenesis
- Others
- Gene Synthesis
- Synthetic Biology
- Vaccine Development
- Genetic Engineering
- Others
- Diagnostics
- Therapeutics
- RNAi Therapies
- Antisense Oligonucleotide-based Therapies
- Others
End Use Outlook (Revenue, USD Million, 2021-2033)
- Biopharmaceutical and Diagnostics Companies
- Academic and Research Institutes
- Contract Research Organizations
Country Outlook (Revenue, USD Million, 2021-2033)
- Saudi Arabia
- UAE
- Kuwait
- Qatar
- Oman
- Rest of Middle East
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Middle East DNA Synthesis Market Variables, Trends & Scope
Chapter 4. Middle East DNA Synthesis Market: Service Type Estimates & Trend Analysis
Chapter 5. Middle East DNA Synthesis Market: Application Estimates & Trend Analysis
Chapter 6. Middle East DNA Synthesis Market: End-Use Estimates & Trend Analysis
Chapter 7. Middle East DNA Synthesis Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies profiled in this Middle East DNA Synthesis market report include:- Thermo Fisher Scientific, Inc.
- LGC Biosearch Technologies
- Eurofins Scientific
- Integrated DNA Technologies, Inc.
- Quintara Biosciences
- AlGenome International
- DNA Script
- Agilent Technologies
- Twist Bioscience
- Bio‑Synthesis Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | August 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 44.7 Million |
| Forecasted Market Value ( USD | $ 143.3 Million |
| Compound Annual Growth Rate | 14.2% |
| Regions Covered | Middle East |
| No. of Companies Mentioned | 11 |
